Elanco Animal Health Inc. — FY 2019 Form 10-K
Business context and reporting period. Elanco develops, manufactures and markets animal-health products for food and companion animals, selling more than 125 brands in over 90 countries. This annual filing covers the fiscal year ended December 31, 2019; it also provides unaudited quarterly results. Elanco became fully independent from Eli Lilly in March 2019, so comparisons with earlier periods are affected by the separation and related transition costs and service arrangements.
Key financial metrics
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $3,071.0 million | $3,066.8 million |
| Gross profit / gross margin | $1,600.7 million / approximately 52.1% | $1,493.0 million / approximately 48.7% |
| Operating income / operating margin | $184.5 million / approximately 6.0% | $185.0 million / approximately 6.0% |
| Net income / diluted EPS | $67.9 million / $0.18 | $86.5 million / $0.28 |
| Cash from operating activities | $224.1 million | $487.3 million |
| Capital expenditures | $140.4 million | $134.5 million |
| Cash and cash equivalents, year-end | $334.0 million | $474.8 million |
| Total debt carrying value, year-end | $2,355.0 million | $2,472.3 million |
| Current assets / current liabilities, year-end | $2,373.1 million / $818.5 million | $2,504.9 million / $970.7 million |
Revenue by product category in 2019: Companion Animal Disease Prevention $787.9 million; Companion Animal Therapeutics $348.0 million; Food Animal Future Protein & Health $745.1 million; Food Animal Ruminants & Swine $1,110.3 million; and Strategic Exits $79.7 million. Food animal products represented approximately 60% of revenue and companion animal products approximately 37%.
Fourth-quarter 2019 revenue was $787.0 million, versus $799.3 million in fourth-quarter 2018. The company reported a fourth-quarter 2019 net loss of $9.5 million, compared with net income of $16.4 million a year earlier.
Material changes versus the prior comparable period
- Full-year revenue was effectively flat, up $4.2 million (0.1%) from 2018. Price contributed 2%, foreign exchange reduced revenue by 2%, and volume was flat; at constant exchange rates, revenue increased 2%.
- Companion Animal Therapeutics revenue rose 23%, driven by demand, particularly for Galliprant, and Aratana products. Food Animal Future Protein & Health increased 5%. These gains were offset by declines in Ruminants & Swine (down 5%) and Disease Prevention (down 2%).
- Gross margin improved as cost of sales fell $103.5 million, primarily from manufacturing productivity improvements and prior-year inventory and facility-related charges. Operating income was broadly unchanged.
- Net income declined $18.6 million. Interest expense increased to $78.9 million from $29.6 million, while asset impairment, restructuring and other special charges rose to $185.5 million from $128.8 million.
- Operating cash flow fell $263.2 million, reflecting lower net income, increased receivables and inventory, and payment timing. Cash used for investing was $234.8 million, including acquisition and software spending; simple operating cash flow less capital expenditures was approximately $83.7 million.
- Shared-class antibiotic revenue was 11% of total revenue in 2019, down from 16% in 2015; animal-only antibiotics and ionophores represented 24%, versus 23% in 2015. Foreign currencies represented approximately 44% of 2019 revenue, and currency movements reduced revenue by 2%.
Outlook, management commentary, risks and unusual items
- Management expected 2020 capital expenditures of approximately $150 million and estimated standalone/separation stand-up costs at $240–$290 million, net of potential real-estate dispositions and employee-benefit changes; a portion was expected to be capitalized.
- Management stated that cash on hand, operating cash flows, existing financing and financing arranged in 2020 were expected to support cash needs for at least the next 12 months. This outlook includes the planned Bayer acquisition and is subject to business and market conditions.
- The pending Bayer Animal Health acquisition was valued at approximately $5.3 billion in cash plus approximately $2.3 billion in Elanco shares, subject to adjustments and regulatory approvals. In January and February 2020, Elanco raised approximately $769.9 million through a common-stock offering and approximately $530.1 million net from tangible equity units, priced a $4.275 billion term loan B and a $750 million revolving facility, and repaid its existing $371.4 million term loan. The acquisition remained pending at the filing date.
- To address antitrust requirements for the Bayer transaction, Elanco agreed to divest Osurnia worldwide and Capstar U.S. rights for $230 million, and announced a planned $55 million divestiture of Vecoxan worldwide. These transactions were expected to close by the end of 2020, subject to conditions.
- Significant risks include generic competition (including new U.S. generic monensin competition for Rumensin), antibiotic-use restrictions and shifting consumer preferences, African Swine Fever and other animal-disease outbreaks, product safety or supply disruptions, distributor inventory and payment-term changes, foreign exchange, and successful integration of acquired businesses. The filing also identified uncertainty about the possible business effects of the emerging coronavirus outbreak in China.
- Unusual expenses included $144.7 million of acquisition transaction and integration costs within special charges, plus restructuring and asset-related costs. R&D spending increased 10% to $270.1 million. The company reported approximately $3.0 billion of goodwill and $2.5 billion of other intangible assets, making impairment assumptions relevant.
- Management reported no litigation liabilities recorded at year-end because no significant claim was considered both probable and estimable. The independent auditor issued an unqualified opinion on the financial statements and internal controls; the internal-control assessment excluded Aratana and Prevtec, which represented approximately 3% of assets and less than 1% of sales.
Important facts for investors to verify
- Whether Bayer acquisition approvals, closing conditions, divestitures and anticipated integration benefits were achieved, and the resulting debt, interest expense and dilution.
- Whether revenue and margins can grow after flat 2019 revenue, especially as generic competition affects Rumensin and product mix and animal-health regulations evolve.
- Whether operating cash flow recovers from the 2019 decline and whether working-capital needs, distributor payment terms and planned capital spending remain manageable.
- Whether the estimated $240–$290 million stand-up cost range and restructuring plans are completed within expectations, and whether productivity gains persist.
- Whether impairment, rebate-estimation, pension-funding and acquisition-valuation assumptions remain supportable; the filing highlights U.S. rebates and discounts as a critical audit matter.